NASDAQ$TNXP
Tonix Pharmaceuticals Holding Corp · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
Reported financial results for the first quarter ended March 31, 2022, and provided an overview of recent operational highlights.
Tonix Pharmaceuticals reported $140.4 million in cash and cash equivalents as of March 31, 2022. The company's R&D expenses were $18.4 million, and G&A expenses were $8.0 million for the first quarter of 2022. Net loss per common share was $0.05.
- Initiated Fibromyalgia Phase 3 Trial of TNX-102 SL, with interim analysis results expected in the first quarter of 2023.
- Long COVID IND was cleared for TNX-102 SL, and Phase 2 trial is expected to start in the second quarter of 2022.
- Three additional CNS programs are expected to initiate Phase 2 studies in 2022: TNX-1300 for Cocaine Intoxication, TNX-1900 for Chronic Migraine, and TNX-102 SL for PTSD.
- FDA granted Orphan-Drug Designation for TNX-2900 for the treatment of Prader-Willi Syndrome.
Headline financials
Revenue & EPS history
Tonix · Revenue · Quarterly
$6.88M
Forward guidance
Tonix Pharmaceuticals anticipates advancing its clinical development programs and investing in its development pipeline throughout 2022.
Tailwinds
- Expects to have five central nervous system (CNS) programs in the clinic by the end of the year.
- TNX-102 SL (cyclobenzaprine HCl sublingual tablets) for fibromyalgia is in mid-Phase 3 development.
- TNX-102 SL trials in Long COVID and PTSD are expected to initiate enrollment in the second quarter of 2022.
- TNX-1300 (recombinant double mutant cocaine esterase) is expected to start enrolling in a Phase 2 trial in the second quarter of 2022.
- TNX-1900 (intranasal potentiated oxytocin) is expected to enter the clinic in the second half of 2022 for the prevention of migraines in chronic migraineurs.
Headwinds
- Risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations.
- Delays and uncertainties caused by the global COVID-19 pandemic.
- Risks related to the timing and progress of clinical development of product candidates.
- Need for additional financing.
- Uncertainties of patent protection and litigation.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2022
-1.2%
Avg return
Earnings day
+0.5%
Avg return
5 days after
-12.7%
Avg return
30 days after
44%
23 / 52 earnings
Positive
+12.9%
Q1 2016
Best reaction
-31.7%
Q1 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.1% | +11.7% | — | |
| Q4 2025 | +0.0% | +19.1% | -2.0% | |
| Q3 2025 | -0.9% | -6.5% | +16.2% | |
| Q1 2025 | +5.2% | +45.9% | +80.0% | |
| Q4 2024 | -2.4% | +48.6% | -23.5% | |
| Q3 2024 | +0.6% | -7.1% | +64.3% | |
| Q2 2024 | -2.6% | -21.7% | -65.2% | |
| Q1 2024 | +4.8% | +17.6% | -79.6% | |
| Q4 2023 | +2.5% | -10.5% | -5.3% | |
| Q3 2023 | -4.3% | -6.1% | -18.4% | |
| Q2 2023 | +1.8% | +1.1% | -4.2% | |
| Q1 2023 | -31.7% | -40.6% | -41.2% | |
| Q4 2022 | +8.7% | -3.2% | -9.7% | |
| Q3 2022 | +1.5% | +4.4% | -17.8% | |
| Q2 2022 | -11.4% | -11.4% | -42.4% | |
| Q1 2022 | -5.4% | -7.1% | -49.3% | |
| Q4 2021 | -4.7% | +9.1% | -13.6% | |
| Q3 2021 | +7.4% | -1.8% | -18.2% | |
| Q2 2021 | +12.5% | -1.4% | -2.9% | |
| Q1 2021 | -2.8% | +0.0% | +22.6% | |
| Q4 2020 | +0.0% | +14.2% | -14.2% | |
| Q3 2020 | -1.8% | +10.7% | +16.1% | |
| Q2 2020 | -12.1% | -12.1% | -30.2% | |
| Q1 2020 | -3.3% | -2.8% | -4.2% | |
| Q4 2019 | -13.2% | -14.1% | -20.0% | |
| Q3 2019 | -3.1% | +0.8% | -59.5% | |
| Q2 2019 | +0.5% | +0.0% | +4.3% | |
| Q1 2019 | -9.5% | -18.0% | -21.0% | |
| Q4 2018 | -8.7% | -19.4% | -15.6% | |
| Q3 2018 | -10.6% | -18.5% | -54.8% | |
| Q2 2018 | -2.9% | +15.2% | -21.0% | |
| Q1 2018 | +6.2% | +11.6% | +48.6% | |
| Q4 2017 | -4.7% | -1.1% | -13.4% | |
| Q3 2017 | -7.9% | -2.2% | +3.3% | |
| Q1 2017 | +0.5% | +4.9% | +3.4% | |
| Q4 2016 | -12.5% | -10.9% | -15.0% | |
| Q3 2016 | +1.3% | -4.5% | -6.8% | |
| Q2 2016 | +9.7% | +23.7% | -58.0% | |
| Q1 2016 | +12.9% | — | — | |
| Q4 2015 | -0.2% | — | — | |
| Q3 2015 | -6.2% | — | — | |
| Q2 2015 | +1.2% | — | — | |
| Q1 2015 | +1.8% | — | — | |
| Q4 2014 | +7.9% | — | — | |
| Q3 2014 | -2.5% | — | — | |
| Q2 2014 | +12.4% | — | — | |
| Q1 2014 | -1.7% | — | — | |
| Q4 2013 | +11.2% | — | — | |
| Q3 2013 | +0.5% | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | +4.7% | — | — | |
| Q1 2012 | -12.0% | — | — | |
| Q4 2012 | +0.0% | — | — | |
| Q3 2011 | — | — | — | |
| Q2 2011 | — | — | — | |
| Q1 2011 | — | — | — | |
| Q4 2010 | — | — | — | |
| Q3 2009 | — | — | — | |
| Q2 2010 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro